$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Comparative analysis of the differences between tovorafenib and dabrafenib and their pharmacological mechanisms, clinical applications and efficacy
2026-02-01 22:25:32
Check Details
Detailed description of the usage and dosage of vorasidenib-VORANIGO and the clinical medication regimen for patients at different stages.
2026-02-01 22:25:32
Check Details
Zongatinib (Zongatinib) dosage and clinical medication regimens for different patients
2026-02-01 22:25:32
Check Details
What is the therapeutic effect of vosoritide and summary analysis of clinical research data, patient experience and efficacy
2026-02-01 22:25:32
Check Details
Analysis of the functions and uses of Methylcobalamin Injection (Rozebalamin) and its performance in the treatment of neuralgia
2026-02-01 22:25:32
Check Details
Comparison of pharmacological differences and clinical use differences between cobimetinib and bimetinib
2026-02-01 22:25:32
Check Details
Do I need to take macitentan (Aopuxil) for life? Doctor’s advice and risk analysis of drug discontinuation
2026-02-01 22:25:32
Check Details
When will Pitolisant be launched in the country? Approval time and sales progress
2026-02-01 22:25:32
Check Details
Detailed description of Pretomanid’s domestic launch time, approval status and marketing progress
2026-02-01 22:25:32
Check Details
Summary of research on whether voclosporin can be used in the treatment of skin diseases and related clinical applications
2026-02-01 22:25:32
Check Details
Analysis of ponatinib 15mg dosage specifications, indications and patient medication reference guide
2026-02-01 22:25:32
Check Details
Analysis of the efficacy of safinamide mesylate tablets (Siddaco) and its application in the treatment of Parkinson's disease
2026-02-01 22:25:32
Check Details
1
2
...
2412
2413
2414
2415
2416
2417
2418
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
2
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
3
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
4
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
5
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
6
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
7
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
8
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
9
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
10
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
11
Zanvastro (zilganersen-alexander) Intrathecal Injection: First Targeted Therapy for Alexander Disease
12
FDA Approves LISRAYA (brepocitinib): First Oral Targeted Therapy for Adults with Dermatomyositis